Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2018, Article ID 5253623, 13 pages
https://doi.org/10.1155/2018/5253623
Review Article

Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials

Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand

Correspondence should be addressed to Pajaree Sriuttha; moc.liamg@jpkoom

Received 24 July 2017; Revised 25 September 2017; Accepted 17 October 2017; Published 15 January 2018

Academic Editor: Maria Buti

Copyright © 2018 Pajaree Sriuttha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. M. Ornbjerg, H. B. Andersen, P. Kryger, and B. Cleal, “What do patients in rheumatologic care know about the risks of NSAIDs?” J Clin Rheumatol: practical reports on rheumatic & musculoskeletal diseases, vol. 14, no. 2, pp. 69–73, 2008. View at Google Scholar
  2. S. Shah and V. Mehta, “Controversies and advances in non-steroidal anti-inflammatory drug (NSAID) analgesia in chronic pain management,” Postgraduate Medical Journal, vol. 88, no. 1036, pp. 73–78, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Zhou, D. M. Boudreau, and A. N. Freedman, “Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population,” Pharmacoepidemiology and Drug Safety, vol. 23, no. 1, pp. 43–50, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. Health Product Vigilance Center, Food and Drug Administration, Adverse Events data from 1984, 2016,http://thaihpvc.fda.moph.go.ththaihvcpublic/News/uploads/hpvc_5_13_0_100591.pdf.
  5. P. Sarges, J. M. Steinberg, and J. H. Lewis, “Drug-induced liver injury: highlights from a review of the 2015 literature,” Drug Safety, vol. 39, no. 9, pp. 801–821, 2016. View at Publisher · View at Google Scholar
  6. A. Techman, “Novartis Withdraws Lumiracoxib (Prexige«) in Australia in Response to Decision From Therapeutic Goods Administration to Cancel Registration,” CIAOMed, 2007. View at Google Scholar
  7. G. Danan and C. Benichou, “Causality assessment of adverse reactions to drugs—I: a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries,” Journal of Clinical Epidemiology, vol. 46, no. 11, pp. 1323–1330, 1993. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Benichou, G. Danan, and A. Flahault, “Causality assessment of adverse reactions to drugs—II: an original model for validation of drug causality assessment methods: case reports with positive rechallenge,” Journal of Clinical Epidemiology, vol. 46, no. 11, pp. 1331–1336, 1993. View at Publisher · View at Google Scholar · View at Scopus
  9. G. P. Aithal, P. B. Watkins, R. J. Andrade et al., “Case definition and phenotype standardization in drug-induced liver injury,” Clinical Pharmacology & Therapeutics, vol. 89, no. 6, pp. 806–815, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Kromann-Andersen and A. Pedersen, “Reported adverse reactions to and consumption of nonsteroidal antiinflammatory drugs in Denmark over a 17 year period,” Dan Med Bull, vol. 35, no. 2, pp. 187–192, 1988. View at Google Scholar
  11. J. H. Rubenstein and L. Laine, “Systematic review: The hepatotoxicity of non-steroidal anti-inflammatory drugs,” Alimentary Pharmacology & Therapeutics, vol. 20, no. 4, pp. 373–380, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Rostom, L. Goldkind, and L. Laine, “Nonsteroidal anti-inflammatory drugs and hepatic toxicity: A systematic review of randomized controlled trials in arthritis patients,” Clinical Gastroenterology and Hepatology, vol. 3, no. 5, pp. 489–498, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. LA. Garcia Rodriguez, S. Perez Gutthann, A. M. Walker, and L. Lueck, “The role of non-steroidal anti-inflammatory drugs in acute liver injury,” BMJ, vol. 305, no. 6858, pp. 865–898, 1992. View at Google Scholar
  14. F. J. De Abajo, D. Montero, M. Madurga, and L. A. García Rodríguez, “Acute and clinically relevant drug-induced liver injury: A population case-control study,” British Journal of Clinical Pharmacology, vol. 58, no. 1, pp. 71–80, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Traversa, C. Bianchi, R. Da Cas, I. Abraha, F. Menniti-Ippolito, and M. Venegoni, “Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs,” BMJ, vol. 327, no. 7405, pp. 18–22, 2003. View at Google Scholar
  16. R. Buxton, D. M. Grennan, and D. G. Palmer, “Fenbufen compared with indomethacin in osteoarthrosis,” Current Medical Research and Opinion, vol. 5, no. 9, pp. 682–687, 1978. View at Publisher · View at Google Scholar · View at Scopus
  17. L. A. Verbruggen, E. Cytryn, and H. Pintens, “Double-Blind Crossover Study of Nabumetone versus Naproxen in the Treatment of Osteoarthritis,” Journal of International Medical Research, vol. 10, no. 4, pp. 214–218, 1982. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Turner, “Hepatic and renal tolerability of long-term naproxen treatment in patients with rheumatoid arthritis,” Seminars in Arthritis and Rheumatism, vol. 17, no. 3, pp. 29–35, 1988. View at Publisher · View at Google Scholar · View at Scopus
  19. W. Eversmeyer, M. Poland, R. E. DeLapp, and C. P. Jensen, “Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis,” American Journal of Medicine, vol. 95, no. 2, pp. 2A10S–2A8S, 1993. View at Google Scholar
  20. A. C. Kennedy, B. J. Mullen, S. H. Roth et al., “A double-blind comparison of the efficacy and safety of ketoprofen extended-release (200 mg once daily) and diclofenac (75 mg twice daily) for treatment of osteoarthritis,” Current Therapeutic Research, vol. 55, no. 2, pp. 119–132, 1994. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Schmitt, K. Walter, and H. J. Kurth, “Clinical trial on the efficacy and safety of different diclofenac formulations: Multiple-unit formulations compared to enteric coated tablets in patients with activated osteoarthritis,” Inflammopharmacology, vol. 7, no. 4, pp. 363–375, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. G. J. Morgan Jr., J. Kaine, R. DeLapp, and R. Palmer, “Treatment of elderly patients with nabumetone or diclofenac: Gastrointestinal safety profile,” Journal of Clinical Gastroenterology, vol. 32, no. 4, pp. 310–314, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. F. McKenna, D. Borenstein, H. Wendt, C. Wallemark, J. B. Lefkowith, and G. S. Geis, “Celecoxib versus diclofenac in the management of osteoarthritis of the knee: A placebo-controlled, randomised, double-blind comparison,” Scandinavian Journal of Rheumatology, vol. 30, no. 1, pp. 11–18, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. D. E. Furst, K. S. Kolba, R. Fleischmann et al., “Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac,” The Journal of Rheumatology, vol. 29, no. 3, pp. 436–446, 2002. View at Google Scholar · View at Scopus
  25. P. S. Tugwell, G. A. Wells, and J. Z. Shainhouse, “Equivalence study of a topical diclofenac solution (pennsaid)compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee:a randomized controlled trial,” Journal of Rheumatology, vol. 31, no. 10, pp. 2002–2012, 2004. View at Google Scholar
  26. A. R. Temple, G. D. Benson, J. R. Zinsenheim, and J. E. Schweinle, “Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis,” Clinical Therapeutics, vol. 28, no. 2, pp. 222–235, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Laine, L. Goldkind, S. P. Curtis, L. G. Connors, Z. Yanqiong, and C. P. Cannon, “How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial,” American Journal of Gastroenterology, vol. 104, no. 2, pp. 356–362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. L. E. Dahlberg, I. Holme, K. Høye, and B. Ringertz, “A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis,” Scandinavian Journal of Rheumatology, vol. 38, no. 2, pp. 133–143, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. J. S. Sampalis and L. A. Brownell, “A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin,” Nutrition Journal , vol. 11, no. 1, article 21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. W. E. Shell, E. H. Charuvastra, M. A. Dewood, L. A. May, D. H. Bullias, and D. S. Silver, “A double-blind controlled trial of a single dose naproxen and an amino acid medical food theramine for the treatment of low back pain,” American Journal of Therapeutics, vol. 19, no. 2, pp. 108–114, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Chopra, M. Saluja, G. Tillu et al., “Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double-blind, controlled equivalence drug trial,” Rheumatology, vol. 52, no. 8, Article ID ket414, pp. 1408–1417, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. R. D. Altman, V. Strand, M. C. Hochberg et al., “Low-dose solumatrix diclofenac in the treatment of osteoarthritis: A 1-year, open-label, phase III safety study,” Postgraduate Medical Journal, vol. 127, no. 5, pp. 517–528, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Pinsornsak, P. Kanokkangsadal, and A. Itharat, “The clinical efficacy and safety of the sahastara remedy versus diclofenac in the treatment of osteoarthritis of the knee: A double-blind, randomized, and controlled trial,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 103046, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. N. P. Chalasani, P. H. Hayashi, H. L. Bonkovsky, V. J. Navarro, W. M. Lee, and R. J. Fontana, “ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury,” American Journal of Gastroenterology, vol. 109, no. 7, pp. 950–966, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Kaplowitz, “Rules and laws of drug hepatotoxicity,” Pharmacoepidemiology and Drug Safety, vol. 15, no. 4, pp. 231–233, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: Is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. W. H. Robinson, C. M. Lepus, Q. Wang et al., “Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis,” Nature Reviews Rheumatology, vol. 12, no. 10, pp. 580–592, 2016. View at Publisher · View at Google Scholar
  38. M. Chen, A. Suzuki, J. Borlak, R. J. Andrade, and M. I. Lucena, “Drug-induced liver injury: Interactions between drug properties and host factors,” Journal of Hepatology, vol. 63, no. 2, pp. 503–514, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. United States Library of Medicine, “Liver Tox Clinical and Research Information on Drug Induced Liver Injury,” 2016, http://livertox.nih.gov.
  40. A. Grieco, L. Miele, A. Giorgi, I. M. Civello, and G. Gasbarrini, “Acute cholestatic hepatitis associated with celecoxib,” Annals of Pharmacotherapy, vol. 36, no. 12, pp. 1887–1889, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. M. V. Galan, S. C. Gordon, and A. L. Silverman, “Celecoxib-induced cholestatic hepatitis [4],” Annals of Internal Medicine, vol. 134, no. 3, p. 254, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Nachimuthu, L. Volfinzon, and L. Gopal, “Acute hepatocellular and cholestatic injury in a patient taking celecoxib,” Postgraduate Medical Journal, vol. 77, no. 910, pp. 548–550, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. F. Bessone, “Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?” World Journal of Gastroenterology, vol. 16, no. 45, pp. 5651–5661, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Merz, K. R. Lee, G. A. Kullak-Ublick, A. Brueckner, and P. B. Watkins, “Methodology to Assess Clinical Liver Safety Data,” Drug Safety, vol. 37, no. 1, pp. 33–45, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. P. A. Schmeltzer, A. S. Kosinski, D. E. Kleiner et al., “Liver injury from nonsteroidal anti-inflammatory drugs in the United States,” Liver International, vol. 36, no. 4, pp. 603–609, 2016. View at Publisher · View at Google Scholar · View at Scopus
  46. G. P. Aithal and C. P. Day, “Nonsteroidal anti-inflammatory drug-induced hepatotoxicity,” Clinics in Liver Disease, vol. 11, no. 3, pp. 563–575, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Bessone, N. Hernandez, M. G. Roma et al., “Hepatotoxicity induced by coxibs: how concerned should we be?” Expert Opinion on Drug Safety, vol. 15, no. 11, pp. 1463–1475, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. P. Soni, B. Shell, G. Cawkwell, C. Li, and H. Ma, “The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: Pooled analysis of 41 randomized controlled trials,” Current Medical Research and Opinion, vol. 25, no. 8, pp. 1841–1851, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. F. E. Silverstein, G. Faich, J. L. Goldstein, L. S. Simon, T. Pincus, A. Whelton et al., “Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study,” Journal of the American Medical Association, vol. 284, no. 10, pp. 1247–1255, 2000. View at Google Scholar